ライフサイエンスコーパス: atherosclerotic cardiovascular disease

1 have an inverse relationship to the risk of atherosclerotic cardiovascular disease.

2 the morbidity and mortality associated with atherosclerotic cardiovascular disease.

3 of the 1p13 SORT1 locus for the treatment of atherosclerotic cardiovascular disease.

4 new therapeutic targets for the treatment of atherosclerotic cardiovascular disease.

5 poiesis correlates with an increased risk of atherosclerotic cardiovascular disease.

6 l mediators that link diabetes mellitus with atherosclerotic cardiovascular disease.

7 y lipoprotein lowering and for prevention of atherosclerotic cardiovascular disease.

8 holesterol is an independent risk factor for atherosclerotic cardiovascular disease.

9 to assess an individual's risk of developing atherosclerotic cardiovascular disease.

10 (HDL-C) are associated with protection from atherosclerotic cardiovascular disease.

11 ion between chronic bacterial infections and atherosclerotic cardiovascular disease.

12 of aging: shingles, Alzheimer's disease and atherosclerotic cardiovascular disease.

13 ated in promoting the metabolic syndrome and atherosclerotic cardiovascular disease.

14 arkedly reduced morbidity and mortality from atherosclerotic cardiovascular disease.

15 n the role of selenium for the prevention of atherosclerotic cardiovascular disease.

16 etabolic abnormalities and increased risk of atherosclerotic cardiovascular disease.

17 sterol is a well established risk factor for atherosclerotic cardiovascular disease.

18 atory target for therapeutic intervention in atherosclerotic cardiovascular disease.

19 ces the incidence of human disorders such as atherosclerotic cardiovascular disease.

20 mal cause of most morbidity and mortality in atherosclerotic cardiovascular disease.

21 he primary and secondary prevention of human atherosclerotic cardiovascular disease.

22 of therapies intended to reduce the risk of atherosclerotic cardiovascular disease.

23 complications of periodontal disease such as atherosclerotic cardiovascular disease.

24 Aspirin is beneficial in the setting of atherosclerotic cardiovascular disease.

25 he mechanistic role of C-reactive protein in atherosclerotic cardiovascular disease.

26 Angiotensin II (Ang II) increases atherosclerotic cardiovascular disease.

27 r their relationship to risk of diabetes and atherosclerotic cardiovascular disease.

28 variety of chronic bacterial infections and atherosclerotic cardiovascular disease.

29 ntative US adult population with established atherosclerotic cardiovascular disease.

30 current myocardial infarction and death from atherosclerotic cardiovascular disease.

31 nd expenditures among those with established atherosclerotic cardiovascular disease.

32 roven benefit to individuals who suffer from atherosclerotic cardiovascular disease.

33 percoagulation, vasculopathy, and ultimately atherosclerotic cardiovascular disease.

34 which diet might influence the occurrence of atherosclerotic cardiovascular disease.

35 ine are associated with an increased risk of atherosclerotic cardiovascular disease.

36 have been implicated in the pathogenesis of atherosclerotic cardiovascular disease.

37 levels are inversely associated with risk of atherosclerotic cardiovascular disease.

38 nts an important independent risk factor for atherosclerotic cardiovascular disease.

39 M), obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

40 ovascular death in patients with established atherosclerotic cardiovascular disease.

41 ients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease.

42 s are effective in the primary prevention of atherosclerotic cardiovascular disease.

43 the aging process and may play a key role in atherosclerotic cardiovascular disease.

44 oprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease.

45 associated with incident type 2 diabetes and atherosclerotic cardiovascular disease.

46 ow-density lipoprotein will decrease risk of atherosclerotic cardiovascular disease.

47 eved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.

48 (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease.

49 lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

50 as the most effective way to reduce risk of atherosclerotic cardiovascular disease.

51 fication of new, modifiable risk factors for atherosclerotic cardiovascular disease.

52 important contributor to the pathobiology of atherosclerotic cardiovascular disease.

53 and personal and family history of premature atherosclerotic cardiovascular disease.

54 n obesity and are positively correlated with atherosclerotic cardiovascular diseases.

55 e of value in the management of diabetes and atherosclerotic cardiovascular diseases.

56 0.672 for ADA HbA1c clinical categories for atherosclerotic cardiovascular disease, 0.701 for ADA fa

57 has been associated with a greater risk for atherosclerotic cardiovascular disease (ACD).

58 on study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 he

59 tion between periodontitis (PD) and incident atherosclerotic cardiovascular disease (ACVD), including

60 th the association between periodontitis and atherosclerotic cardiovascular disease (ACVD).

61 Association endorses statins for adults with atherosclerotic cardiovascular disease, adults with LDL

62 volocumab vs placebo in patients with stable atherosclerotic cardiovascular disease and a baseline LD

63 Primary end points were atherosclerotic cardiovascular disease and all-cause mor

64 significant impact in the adult population, atherosclerotic cardiovascular disease and death are rar

65 than the general population for accelerated atherosclerotic cardiovascular disease and for restenosi

66 iation study on stools from individuals with atherosclerotic cardiovascular disease and healthy contr

67 Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incomplete

68 Furthermore, as this population ages, atherosclerotic cardiovascular disease and its risk fact

69 trolled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholester

70 multiple lipid abnormalities associated with atherosclerotic cardiovascular disease and optimizing ca

71 tion may reduce tHcy and potentially prevent atherosclerotic cardiovascular disease and other disease

72 e most important and common risk factors for atherosclerotic cardiovascular disease and renal disease

73 ndrome, a cluster of potent risk factors for atherosclerotic cardiovascular disease and type 2 diabet

74 system are important in the pathogenesis of atherosclerotic cardiovascular disease, and that interve

75 ma high-density lipoprotein (HDL) levels and atherosclerotic cardiovascular disease are poorly unders

76 (LDL-C) >/=190 mg/dL are at a higher risk of atherosclerotic cardiovascular disease as a result of lo

77 re associated with prevalent and subclinical atherosclerotic cardiovascular disease, as well as its r

78 Atherosclerotic cardiovascular disease (ASCVD) affects m

79 zygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) and have

80 statin treatment for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and proba

81 determine estimated 10-year absolute risk of atherosclerotic cardiovascular disease (ASCVD) and to de

82 ups of patients have enhanced propensity for atherosclerotic cardiovascular disease (ASCVD) associate

83 oward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implem

84 Atherosclerotic cardiovascular disease (ASCVD) continues

85 a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by

86 is vital in therapy for patients at risk for atherosclerotic cardiovascular disease (ASCVD) events gi

87 -reactive protein (CRP) in the prediction of atherosclerotic cardiovascular disease (ASCVD) events in

88 on (ACC/AHA) Pooled Cohort Risk Equation for atherosclerotic cardiovascular disease (ASCVD) events in

89 oronary artery calcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, a

90 Atherosclerotic cardiovascular disease (ASCVD) events, i

91 ession of coronary calcification and prevent atherosclerotic cardiovascular disease (ASCVD) events.

92 e hypothesis that mortality rates related to atherosclerotic cardiovascular disease (ASCVD) in dialys

93 Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in famili

94 ations to estimate 10-year absolute risk for atherosclerotic cardiovascular disease (ASCVD) in primar

95 Atherosclerotic cardiovascular disease (ASCVD) is associ

96 Accurate risk assessment of atherosclerotic cardiovascular disease (ASCVD) is essent

97 Atherosclerotic cardiovascular disease (ASCVD) is the le

98 y function is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) outcomes

99 in 200 individuals in the United States, but atherosclerotic cardiovascular disease (ASCVD) outcomes

100 therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk >/=7

101 Besides age, other discriminators of atherosclerotic cardiovascular disease (ASCVD) risk are

102 women 45 to 84 years of age without clinical atherosclerotic cardiovascular disease (ASCVD) risk at e

103 rt Association cholesterol guidelines to the atherosclerotic cardiovascular disease (ASCVD) risk esti

104 se has engendered interest in nontraditional atherosclerotic cardiovascular disease (ASCVD) risk fact

105 the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in a

106 Although atherosclerotic cardiovascular disease (ASCVD) risk in e

107 ng that they may play a role in the elevated atherosclerotic cardiovascular disease (ASCVD) risk in t

108 The use of atherosclerotic cardiovascular disease (ASCVD) risk to p

109 individuals with a higher 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk, cal

110 reatment with statins to a 7.5% 10-year hard atherosclerotic cardiovascular disease (ASCVD) risk.

111 L)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk.

112 heterogeneity among individuals for CHD and atherosclerotic cardiovascular disease (ASCVD) risk.

113 g from beliefs that these lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) to being

114 recommend initiating primary prevention for atherosclerotic cardiovascular disease (ASCVD) with stat

115 tions for treating adults without history of atherosclerotic cardiovascular disease (ASCVD) with stat

116 n codes for ischemic heart disease (IHD) and atherosclerotic cardiovascular disease (ASCVD), as well

117 In patients with atherosclerotic cardiovascular disease (ASCVD), guidelin

118 between neighborhood disadvantage and major atherosclerotic cardiovascular disease (ASCVD)-related e

119 sclerosis enrolled 6814 adults without known atherosclerotic cardiovascular disease (ASCVD).

120 Approximately 97% of patients had atherosclerotic cardiovascular disease (ASCVD).

121 vel therapeutic opportunity for treatment of atherosclerotic cardiovascular disease (ASCVD).

122 ears to identify those at increased risk for atherosclerotic cardiovascular disease (ASCVD).

123 mainstay in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD).

124 recommended for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

125 length (TL) in leukocytes is associated with atherosclerotic cardiovascular disease (ASCVD).

126 or individuals with >/=7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD).

127 an individuals with subclinical and clinical atherosclerotic cardiovascular disease (ASCVD).

128 n genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD).

129 comprehensively in the prevention of primary atherosclerotic cardiovascular disease (ASCVD).

130 rt pathway, is independently associated with atherosclerotic cardiovascular disease (ASCVD).

131 For example, the new focus on total atherosclerotic cardiovascular diseases (ASCVD) is now i

132 DL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease [ASCVD], diabetes

133 rotected against thrombotic complications of atherosclerotic cardiovascular disease because of reduce

134 should be used with caution in patients with atherosclerotic cardiovascular disease because they may

135 These findings show that patients with atherosclerotic cardiovascular disease benefit from lowe

136 ce provide incremental information regarding atherosclerotic cardiovascular disease beyond current Na

137 evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature o

138 hlamydia pneumoniae has been associated with atherosclerotic cardiovascular disease by both seroepide

139 HDL lowers the risk for atherosclerotic cardiovascular disease by promoting chol

140 In patients with atherosclerotic cardiovascular disease, circulating leve

141 predictor of coronary heart disease and all atherosclerotic cardiovascular disease combined outcomes

142 recently defined, clinical risk factors for atherosclerotic cardiovascular disease; consider current

143 ments in 2 subgroups of patients with stable atherosclerotic cardiovascular disease currently receivi

144 nisms by which obesity increases the risk of atherosclerotic cardiovascular disease (CVD) are poorly

145 1 has been implicated in the pathogenesis of atherosclerotic cardiovascular disease (CVD) based on st

146 are commonly used to assess risk of specific atherosclerotic cardiovascular disease (CVD) events, ie,

147 The lifetime risk of atherosclerotic cardiovascular disease (CVD) for persons

148 Lifetime risk for atherosclerotic cardiovascular disease (CVD) has not pre

149 oprotein B (apoB) have been shown to predict atherosclerotic cardiovascular disease (CVD) in adults e

150 risk alleles significantly increase risk for atherosclerotic cardiovascular disease (CVD) in African

151 Atherosclerotic cardiovascular disease (CVD) is a major

152 A hallmark of atherosclerotic cardiovascular disease (CVD) is the accu

153 rt risk equations were developed to estimate atherosclerotic cardiovascular disease (CVD) risk and gu

154 in or its components may protect against the atherosclerotic cardiovascular disease (CVD) risk factor

155 Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is

156 tin therapy to those at the highest absolute atherosclerotic cardiovascular disease (CVD) risk.

157 a role in the preclinical pathophysiology of atherosclerotic cardiovascular disease (CVD), an inflamm

158 d the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little pro

159 heritable traits and major risk factors for atherosclerotic cardiovascular disease (CVD).

160 poptosis are critical in the pathogenesis of atherosclerotic cardiovascular disease (CVD).

161 The primary end point was atherosclerotic cardiovascular disease, defined as a fir

162 Because clinical atherosclerotic cardiovascular disease does not manifest

163 th Pooled Cohort Equations-predicted 10-year atherosclerotic cardiovascular disease event risk <5% (o

164 ntal value to current practice guidelines in atherosclerotic cardiovascular disease event risk predic

165 Primary outcome was an atherosclerotic cardiovascular disease event, and second

166 Over a follow-up of 3 years, 19 atherosclerotic cardiovascular disease events (9 strokes

167 ndently associated with a 3-fold increase in atherosclerotic cardiovascular disease events among PLWH

168 s associated with a 3-fold increased risk of atherosclerotic cardiovascular disease events and a 4-fo

169 prevention and the effect of lipid drugs on atherosclerotic cardiovascular disease events and advers

170 Coronary EBCT predicts future atherosclerotic cardiovascular disease events in asympto

171 total of 10 470 men and women without prior atherosclerotic cardiovascular disease events or heart f

172 iation Pooled Cohort Equations in predicting atherosclerotic cardiovascular disease events.

173 ical data included baseline lipid levels and atherosclerotic cardiovascular disease events.

174 essive phenotypes with higher LDL-C and more atherosclerotic cardiovascular disease events.

175 standard background therapy in patients with atherosclerotic cardiovascular disease exceeds generally

176 nge of disorders, including type 2 diabetes, atherosclerotic cardiovascular disease, fatty liver dise

177 Current guidelines for atherosclerotic cardiovascular disease focus on high-int

178 ths from cardiac causes that were related to atherosclerotic cardiovascular disease, from a daily ave

179 and diabetes or a 10-year predicted risk for atherosclerotic cardiovascular disease >/=7.5% estimated

180 e prevalence of traditional risk factors for atherosclerotic cardiovascular diseases has been increas

181 The metabolic syndrome and atherosclerotic cardiovascular disease have long been li

182 abetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new

183 ry intake plays a role in the development of atherosclerotic cardiovascular disease; however, few stu

184 ia, and a predisposition to type 2 diabetes, atherosclerotic cardiovascular disease, hypertension, an

185 narios including estimating initial risk for atherosclerotic cardiovascular disease in a primary prev

186 e available on their relation to subclinical atherosclerotic cardiovascular disease in humans.

187 The markedly increased prevalence of atherosclerotic cardiovascular disease in patients with

188 which was shown to inversely correlate with atherosclerotic cardiovascular disease in populations wi

189 is crucial for the reduction in the risk of atherosclerotic cardiovascular disease in the population

190 serum low-density lipoprotein and, thereby, atherosclerotic cardiovascular diseases in obese humans.

191 izing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke

192 widely recognized as a major risk factor for atherosclerotic cardiovascular disease, including subcli

193 Atherosclerotic cardiovascular disease is a leading caus

194 Mortality from atherosclerotic cardiovascular disease is lower in preme

195 rongest association with LDL cholesterol and atherosclerotic cardiovascular disease is the 1p13 sorti

196 Atherosclerotic cardiovascular disease is the leading ca

197 The impact of this on atherosclerotic cardiovascular diseases is not known.

198 single most important genetic risk factor), atherosclerotic cardiovascular disease, Lewy body dement

199 rmone replacement therapy with reductions in atherosclerotic cardiovascular disease may be attributab

200 Beneficial effects of fish oil diets in atherosclerotic cardiovascular disease may involve impro

201 Age-related maculopathy and atherosclerotic cardiovascular disease may share common

202 he glitazones can prevent or delay premature atherosclerotic cardiovascular disease, morbidity, and d

203 High BP is a major risk factor for atherosclerotic cardiovascular disease mortality in the

204 rcANRIL), which is transcribed at a locus of atherosclerotic cardiovascular disease on chromosome 9p2

205 nt with a strong family history of premature atherosclerotic cardiovascular disease or genetic dyslip

206 ssociation between periodontal infection and atherosclerotic cardiovascular disease or its sequelae.

207 x capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a lar

208 Hypertension contributes to all of the major atherosclerotic cardiovascular disease outcomes increasi

209 included age >65 years (P<0.01), history of atherosclerotic cardiovascular disease (P<0.01), prescri

210 ank type 2 diabetes are at increased risk of atherosclerotic cardiovascular disease, partially due to

211 Atherosclerotic cardiovascular disease patients reportin

212 ardiovascular events in patients with stable atherosclerotic cardiovascular disease regardless of whe

213 Atherosclerotic cardiovascular disease remains a major p

214 th familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additio

215 Atherosclerotic cardiovascular disease results in >19 mi

216 symptomatic adults-even those with a 10-year atherosclerotic cardiovascular disease risk below 7.5%.

217 PDAY scores, reflecting increased aggregate atherosclerotic cardiovascular disease risk factor burde

218 he clinician and patient about potential for atherosclerotic cardiovascular disease risk reduction be

219 cohort risk equations were used to estimate atherosclerotic cardiovascular disease risk score based

220 The median 10-year atherosclerotic cardiovascular disease risk score of the

221 adolescents may be susceptible to aggregate atherosclerotic cardiovascular disease risk, as measured

222 rotein inhibitors have also failed to reduce atherosclerotic cardiovascular disease risk, despite pro

223 ment of LDL cholesterol for the reduction in atherosclerotic cardiovascular disease risk, which are i

224 senting 18.3 million adults with established atherosclerotic cardiovascular disease (self-reported or

225 We tested the hypothesis that ARM and atherosclerotic cardiovascular disease share molecules a

226 All patients with atherosclerotic cardiovascular disease should be conside

227 athophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have bee

228 ent and is associated with a greater risk of atherosclerotic cardiovascular disease than any of its i

229 her in people with prevalent and subclinical atherosclerotic cardiovascular disease than in those who

230 guidelines incorporate a new risk score for atherosclerotic cardiovascular disease that includes str

231 s for Primary and/or Secondary Prevention of Atherosclerotic Cardiovascular Disease was to evaluate t

232 ns of disturbed flow are the focal points of atherosclerotic cardiovascular disease, we hypothesized

233 ment, patients who were older, male, and had atherosclerotic cardiovascular disease were more likely

234 effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to sta

235 s to thromboembolic events in the setting of atherosclerotic cardiovascular disease, which is often p

236 se, using US clinical practice patients with atherosclerotic cardiovascular disease with low-density